Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
ORTHO TRI-CYCLEN LO is an oral contraceptive tablet containing a norgestimate/ethinyl estradiol combination in a triphasic formulation. It is indicated for the prevention of pregnancy in women of reproductive age. The drug works by suppressing ovulation through hormonal inhibition of the luteinizing hormone surge.
Product approaching loss of exclusivity; team likely transitioning toward retention and generic defense strategies with moderate competitive pressure (30%).
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
Working on ORTHO TRI-CYCLEN LO offers limited growth trajectory as the product approaches loss of exclusivity with minimal linked job openings. Career value lies in defending market share, managing generic transition, and executing lifecycle management strategies rather than driving innovation or market expansion.
Worked on ORTHO TRI-CYCLEN LO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.